Argus Investors Counsel Inc. Has $3.99 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Argus Investors Counsel Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,837 shares of the company’s stock after selling 931 shares during the quarter. Eli Lilly and Company makes up about 2.6% of Argus Investors Counsel Inc.’s investment portfolio, making the stock its 6th largest position. Argus Investors Counsel Inc.’s holdings in Eli Lilly and Company were worth $3,986,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Simon Quick Advisors LLC increased its stake in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $363,000. Liontrust Investment Partners LLP acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $8,326,000. WASHINGTON TRUST Co increased its stake in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares during the period. Finally, Armstrong Fleming & Moore Inc acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $357,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $777.96 on Monday. The company has a market capitalization of $739.19 billion, a price-to-earnings ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $334.58 and a 12 month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock’s 50 day moving average is $737.05 and its 200-day moving average is $639.53.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.09 earnings per share. Equities research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the sale, the insider now directly owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 195,055 shares of company stock valued at $125,254,657 over the last 90 days. 0.13% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley lifted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Check Out Our Latest Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.